Dissertation > Excellent graduate degree dissertation topics show

Expressions of RKIP and E-cadherin in Prostate Cancer and Their Significance

Author: LuShenXiu
Tutor: ZhongKuangZuo
School: Central South University
Course: Surgery
Keywords: prostate cancer RKIP E-cadherin metastasis Gleason score
CLC: R737.25
Type: Master's thesis
Year: 2008
Downloads: 122
Quote: 0
Read: Download Dissertation

Abstract


Object:To investigate the expressions of RKIP(Raf kinase inhibitor protein)and E-cadherin(Epithelial cadherin)in prostate cancer tissues and the correlation between them.To evaluate RKIP and E-cadherin’s relationship with prostate cancer’s clinical periodization and pathological classification,and probe into the mechanism of RKIP’s suppression of cancer metastasis.Materials and Methods:Collected prostate cancer tissue specimens totalling 26,embedded in ceresin wax,which were verified by pathological diagnosis as experimental group.And collected 14 prostate proliferation tissue specimens,embedded in ceresin wax,which were verified by pathological diagnosis as control group.Immunofluorescence histochemistry staining was adopted as detection method,and the first antibodies used were respectively goat anti-human RKIP antibody and rabbit anti-human E-cadherin antibody while the second antibodies used were respectively FITC-labeled rabbit anti-goat IgG and TRITC-labeled goat anti-rabbit IgG.Used professional image measuring software Image-Pro Plus 6.0 to successively analyze and measured the fluorescent photos collected.Calculated the positive fluorescent areas’ mean densities [mean density=(IOD SUM)/(area sum)],which represented the expression levels of RKIP and E-cadherin in corresponding tissues. Statistical analysises were performed with the use of SPSS 12.0 software, two specimen equal numbers were tested by T-test,correlative analysis between two variable quantities were analyzed by pearson-analysis,and for all statistical tests,the level of significance was set at P＜0.05.Results:1.RKIP expression in prostate cancer and benign prostatic hypertrophy tissue specimens:Immunofluorescence histochemistry staining’s mean density was 0.06515±0.012597 in 26 prostate cancer tissue specimens while the value was 0.07655±0.010970 in 14 benign prostatic hypertrophy tissue specimens,there are conspicuous statistical significance of the positive expression difference between the experimental group and the control group(P＜0.05).2.RKIP expression in prostate cancer’s benign differentiation group and malign differentiation group:Immunofluorescence histochemistry staining’s mean density was 0.07208±0.013283 in 12 prostate cancer tissue specimens of benign differentiation group while the value was 0.05921±0.008577 in 14 prostate cancer tissue specimens of malign differentiation group,there are conspicuous statistical significance of the positive expression difference between the benign differentiation group and the malign differentiation group(P＜0.05).3.RKIP expression in prostate cancer’s invasive metastasis group and non-invasive metastasis group:Immunofluorescence histochemistry staining’s mean density was 0.06000±0.010622 in 13 prostate cancer tissue specimens of invasive metastasis group while the value is 0.07031±0.012658 in 13 prostate cancer tissue specimens of non-invasive metastasis group,there are conspicuous statistical significance of the positive expression difference between the invasive metastasis group and the non-invasive metastasis group.4.E-cad expression in prostate cancer and benign prostatic hypertrophy tissue specimens:Immunofluorescence histochemistry staining’s mean density is 0.04977±0.012346 in 26 prostate cancer tissue specimens while the value is 0.05917±0.009554 in 14 benign prostatic hypertrophy tissue specimens,there are conspicuous statistical significance of the positive expression difference between the experimental group and the control group(P＜0.05).5.E-cad expression in prostate cancer’s benign differentiation group and malign differentiation group:Immunofluorescence histochemistry staining’s mean density was 0.05567±0.013553 in 12 prostate cancer tissue specimens of benign differentiation group while the value was 0.04471±0.008835 in 14 prostate cancer tissue specimens of malign differentiation group,there are conspicuous statistical significance of the positive expression difference between the benign differentiation group and the malign differentiation group(P＜0.05).6.E-cad expression in prostate cancer’s invasive metastasis group and non-invasive metastasis group: Immunofluorescence histochemistry staining’s mean density was 0.05500±0.012767 in 13 prostate cancer tissue specimens of invasive metastasis group while the value was 0.04454±0.009761 in 13 prostate cancer tissue specimens of non-invasive metastasis group,there are conspicuous statistical significance of the positive expression difference between the invasive metastasis group and the non-invasive metastasis group(P＜0.05).7.Analysis of correlation between RKIP expression and E-cad expression in 26 prostate cancer tissue specimens:analysis showed a obvious correlation between RKIP expression and E-cad expression in prostate cancer tissue specimens(r=0.0491,p=0.011＜0.05)Conclusions:1.RKIP is a novel metastasis suppressor gene,its decreased expression can increase prostate cancer’s invasive capability and suppress prostate cancer’s differentiation.2.E-cad is a classic metastasis suppressor factor,its decreased expression can increase prostate cancer’s invasive capability,and its expression level is positively associated with the differentiation of prostate cancer.3.RKIP expression is obviously associated with E-cad expression in prostate cancer,the mechanism of RKIP’s suppression of prostate cancer metastasis may lies in its indirectly regulating the expression of classic tumor metastasis correlation factors including E-cad,VEGF by influencing the signaling pathways such as Raf,TGF-β,etc.

Related Dissertations

  1. The Regulate and Controlof Slug on P53-MDM2 System,R730.2
  2. Research on BT Toxin Oligomer Formation Induced by Lipid Raft and the Immunodetection Explore of Cadherin,S476.1
  3. Fitness Costs of a Disrupted Cadherin Allele Conferring Cry1Ac Resistance of Helicoverpa Armigera,S435.622.3
  4. The Value of Diagnosis for Prostate Cancer by Combined Use of MRS and DWI,R737.25
  5. The Contribution of the CCl22, CCR4 in the Milky Spots Peritoneal -metastasis of Gastric Cancer,R735.2
  6. Clinical Analysis of Postoperative Recurrent-metastatic Gastrointestinal Stromal Tumors,R735
  7. The Expression of PI3K and P53 in Prostate Cancer and Its Clinical Significance,R737.25
  8. The Study on Expression of CLIC1 on Lymphatic Metastasis of Mouse Hepatocarcinoma,R735.7
  9. The Location and Expression in Mouse Heptocarcinoma Cell Lines with High and Low Lymphatic Metastatic Potentials.,R735.7
  10. The Study of the Correlation of Prognosis and Pattern Evaluation of Patients with Recurrence of Rectum Cancer,R735.37
  11. Isoflavone intake and the risk of breast and prostate cancer Meta-analysis,R737.25
  12. α1, 3 fucosyl transferase Ⅳ (Fut4) upregulated increased metastatic potential of squamous cell scc12,R730.2
  13. CXCR1/CXR2 receptor antagonists on mouse ascites hepatoma lymphatic metastatic potential impact,R735.7
  14. Retinoic acid and matrine intervention rat hepatoma change process β-catenin, E-cadherin, MMP-7 dynamic changes,R735.7
  15. Application of Functional MR Imaging in Diagnose for Prostate Cancer,R737.25
  16. Research on the Function of Myosin X in Tumor Invasive Growth,R730.2
  17. Gnrh Migration Is Influenced by the Interaction of Myo X and N-Cadherin,Q42
  18. Study of DSC-PWI in Differential Diagnosis of Lymph Node Lesions and Evaluation after Radiotherapy in Animal Models,R445.2
  19. The Expression and the Clinical Significance of Integrin αvβ3/αvβ5 in the Prostate Cancer Tissues,R737.25
  20. Study on the Expression and Clinical Signification of CXCR4、SDF-1 and E-Cadherin in Gastric Cancer by Tissue Microarray,R735.2
  21. The Animal Study of Biological Active Peptide RGDS Inhibits Colorectal Cancer from Liver Metastases,R735.34

CLC: > Medicine, health > Oncology > Genitourinary tumors > Male genitalia tumors > Prostate cancer
© 2012 www.DissertationTopic.Net  Mobile